Cell No. : Cell Name
RCB2853 : WEHI-3B
update : 2023/10/16
|
| Comment | Mouse cell line derived from myelomonocytic leukemia cells. BALB/c strain. TKG0584 (Deposited from Tohoku Univ.). |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Fukuda, Hiroshi
|
| Originator |
Warner, N.L.
|
| Year of deposit |
2008
|
| Original cell |
TKG0584
|
| Animal |
_mouse
< Mammals
|
| Strain name |
BALB/c
|
| Tissue |
myelomonocyte
|
| Disease name |
myelomonocytic leukemia cell lin
|
| Classification |
cancer
|
| History |
Cell Resource Center for Biomedical Research, Tohoku University（TKG0584）
|
|
Lifespan |
infinite
|
| Morphology |
other
|
| Cellosaurus(Expasy) |
CVCL_2239
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent/Suspension cells
|
| Culture medium |
|
RPMI1640 + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
dilution
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| SSLP(mouse) |
|
OK
|
| Isozyme |
|
LD, NP
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
6
|
| User's Publication |
4
|
| Reference |
|
5288
Shimizu T, Izumi T, Seyama Y, Tadokoro K, Rådmark O, Samuelsson B.
Characterization of leukotriene A4 synthase from murine mast cells: evidence for its identity to arachidonate 5-lipoxygenase.
Proc Natl Acad Sci U S A
1986
83(12):4175-9
PubMed ID: 3012557
DOI: 10.1073/pnas.83.12.4175
|
|
5287
McKean DJ, Infante AJ, Nilson A, Kimoto M, Fathman CG, Walker E, Warner N.
Major histocompatibility complex-restricted antigen presentation to antigen-reactive T cells by B lymphocyte tumor cells.
J Exp Med
1981
154(5):1419-31
PubMed ID: 6170720
DOI: 10.1084/jem.154.5.1419
|
|
1294
Ralph P, Nakoinz I
Direct toxic effects of immunopotentiators on monocytic, myelomonocytic, and histiocytic or macrophage tumor cells in culture.
Cancer Res
1977
37:546-50
PubMed ID: 318922
|
|
716
Ralph P, Nakoinz I
Antibody-dependent killing of erythrocyte and tumor targets by macrophage-related cell lines: enhancement by PPD and LPS.
J Immunol
1977
119:950-54
PubMed ID: 894031
|
|
1141
Ralph P, Moore, M A, Nilsson K
Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines.
J Exp Med
1976
143:1528-33
PubMed ID: 1083890
DOI: 10.1084/jem.143.6.1528
|
|
5289
Metcalf D, Moore MA, Warner NL.
Colony formation in vitro by myelomonocytic leukemic cells.
J Natl Cancer Inst
1969
43(4):983-1001
PubMed ID: 5259326
|
| User's Publication |
|
21565
Yamaguchi M, Sera Y, Toga-Yamaguchi H, Kanegane H, Iguchi Y, Fujimura K.
Knockdown of the Shwachman-Diamond syndrome gene, SBDS, induces galectin-1 expression and impairs cell growth.
Int J Hematol
2024
PubMed ID: 38240987
DOI: 10.1007/s12185-024-03709-z
|
|
12115
Hirai N, Sasaki T, Okumura S, Minami Y, Chiba S, Ohsaki Y.
Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers.
Front Oncol
2020
PubMed ID: 32300555
DOI: 10.3389/fonc.2020.00419
|
|
9506
Nakaoku T, Kohno T, Araki M, Niho S, Chauhan R, Knowles PP, Tsuchihara K, Matsumoto S, Shimada Y, Mimaki S, Ishii G, Ichikawa H, Nagatoishi S, Tsumoto K, Okuno Y, Yoh K, McDonald NQ, Goto K.
A secondary RET mutation in the activation loop conferring resistance to vandetanib.
Nat Commun
2018
9:625
PubMed ID: 29434222
DOI: 10.1038/s41467-018-02994-7
|
|
14651
Shimada Y, Kohno T, Ueno H, Ino Y, Hayashi H, Nakaoku T, Sakamoto Y, Kondo S, Morizane C, Shimada K, Okusaka T, Hiraoka N.
An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma
Oncologist
2017
22(2):158-164
PubMed ID: 28167572
DOI: 10.1634/theoncologist.2016-0194
|
Back
Top
CELL BANK Website
